Physiotherapist struck off for Botox jabs
A leading physiotherapist and former director of a Stourbridge-based rehabilitation clinic was struck off for giving prescription-only Botox injections for more than a decade without authorisation.
Adrian Harding was struck off by the Health and Care Professions Council (HCPC) for administering the injections to treat patients with spasticity between 2008 and 2020 without a prescription or written consent.
He was described as an "extremely experienced" physiotherapist at NPP Neuro Group, which sees patients throughout the West Midlands.
The tribunal found Mr Harding "acted as he pleased" and administered injections despite knowing the drug needed a prescription that he was unable to provide.
A fellow physiotherapist, Dawn Hicklin, supplied Mr Harding with two boxes of injection vials while she was working at City Hospital for Sandwell and West Birmingham NHS Trust in January 2019, the panel heard.
The incident was reported and she was struck off.
Ms Hicklin lied to bosses, the panel said, claiming that the boxes were empty, and that she had not previously provided him with any drug vials.
Following this, in early 2020, Mr Harding told NPP Neuro Group that he would likely be called as a witness as part of an investigation into Ms Hicklin, and that there was "no cause for concern".
By October, he revealed inquiries would be extended to his practice.
Colleagues at NPP Euro Group subsequently audited his records as part of the investigation, and were left in "shock, horror and disbelief" by what they found, the tribunal heard.
The panel said he was "angry" at his employer for raising concerns and "demonstrated a complete lack of insight" of the potential damage he had caused.
Mr Harding was an "acknowledged specialist in his field and lectured on the subject", the HCPC panel was told, and it was likely he "authored the policies that he should have been following and that he had lectured students on such matters".
His record-keeping was described as "so poor it was serious enough to be classed as misconduct".
It was said that many essential records were either missing or incomplete.
Mr Harding was referred to the HCPC on 9 October 2020 by his employer, and self-referred a day later, before retiring by 12 October.
The tribunal found he had not shown any evidence of "reflection, remediation, insight or remorse" and he "simply walked away".
Follow BBC Birmingham on BBC Sounds, Facebook, X and Instagram.
Paramedic failed to take paralysed man to hospital
Radiographer struck off for racist language
Health and Care Professions Tribunal Service
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Revelation-Backed Omada Health Jumps After $150 Million IPO
(Bloomberg) -- Omada Health Inc. shares ended their debut trading day exactly where they started after the digital health-care company raised $150 million in its initial public offering. Next Stop: Rancho Cucamonga! ICE Moves to DNA-Test Families Targeted for Deportation with New Contract Where Public Transit Systems Are Bouncing Back Around the World US Housing Agency Vulnerable to Fraud After DOGE Cuts, Documents Warn Trump Said He Fired the National Portrait Gallery Director. She's Still There. The stock climbed 21% to close at $23 on Friday in New York — the same price it opened at — higher than its IPO price of $19 per share. The stock had jumped as much as 49% during the the trading session. The San Francisco-based company sold 7.9 million shares at $19 each after offering them at $18 to $20 apiece, according to its filings with the US Securities and Exchange Commission. The trading gives Omada a market value of $1.3 billion based on the number of outstanding shares listed in its filings. The IPO adds to the growing pace of US first-time share sales this year, which have raised around $24.9 billion so far, versus $17.6 billion in the same period last year, according to data compiled by Bloomberg. Shares of health-care upstarts that went public on US exchanges this year are also up by a weighted average of roughly 18%, according to Bloomberg calculations. An IPO last month for digital physical therapy provider Hinge Health Inc. — a competitor to Omada — raised $503 million, and shares have risen about 19% since its debut. Omada's offering closed with orders for more than 15 times the shares available, with allocations going to a highly concentrated group of investors, Bloomberg News has reported. Virtual Care Founded in 2011, Omada provides virtual care in between doctor's visits to help people manage chronic conditions including diabetes and prediabetes, obesity, hypertension and musculoskeletal conditions, according to the filing. Users track metrics including weight, blood pressure and blood glucose values to the company's platform, which includes a mobile app. Unlike other digital health firms, Omada doesn't offer GLP-1 weight loss drugs, the filing shows. Instead it has programs to support people using them, including coaching and nutrition guidance, to manage muscle loss and stop the weight from returning when they cease taking the medication, according to the filing. About 50,000 of Omada's 679,000 members are on GLP-1s, co-founder and Chief Executive Officer Sean Duffy said in an interview with Bloomberg News. It's a relatively new business for the company that has expanded in the past year as part of its partnership with Cigna Group's Express Scripts unit, he said. 'For support, especially in chronic disease, it's very helpful that someone feels they are not just doing this for themselves but for someone else - to have someone rooting for you in your corner is really important for outcomes,' Duffy said. Omada is using AI to automate the virtual care it provides to chronic disease sufferers, though the services are 'human-led,' he said. 'Our members tell us they want a person and I am yet to see anyone that feels accountable to ChatGPT,' Duffy said. Omada has over 2,000 customers including employers and health systems, and more than 679,000 total members enrolled in one or more programs, according to the filing. Largest Shareholder Revelation Partners is Omada's largest shareholder, beneficially owning 10.9% of the company before the offering, according to the filing. USVP has 9.9% of the shares, Andreessen Horowitz has 9.6% and FMR has 9.3%, the filing shows. Omada was valued at more than $1 billion in a 2022 funding round led by Fidelity Management & Research Co., it said in a statement at the time. The company had a net loss of $9.4 million on revenue of close to $55 million in the first three months of 2025, compared with a net loss of nearly $19 million on revenue of $35.1 million in the same period a year earlier, the filing shows. The offering was led by Morgan Stanley, Goldman Sachs Group Inc. and JPMorgan Chase & Co., the filing shows. The company's shares trade on the Nasdaq Global Market under the symbol OMDA. (Updates with closing prices.) Cavs Owner Dan Gilbert Wants to Donate His Billions—and Walk Again The SEC Pinned Its Hack on a Few Hapless Day Traders. The Full Story Is Far More Troubling YouTube Is Swallowing TV Whole, and It's Coming for the Sitcom Is Elon Musk's Political Capital Spent? Trump Considers Deporting Migrants to Rwanda After the UK Decides Not To ©2025 Bloomberg L.P.
Yahoo
an hour ago
- Yahoo
Victoria's Voice Foundation addresses naloxone importance on Capital Hill
In an effort to raise awareness of the importance of naloxone, the Orlando-based Victoria's Voice Foundation was on Capitol Hill Friday for National Naloxone Awareness Day. The Victoria's Voice Foundation was founded by David Siegel and his wife after losing their daughter, Victoria, to an overdose. The foundation was one of many ways Siegel gave back to the community. 'Quite literally, with the use of this medicine, as innocent and as easy to administer as it is, you can reverse the effects of an overdose or poisoning immediately, giving somebody else and their family a second shot at life,' said Seminole County Sheriff Dennis Lemma. The Victoria's Voice Foundation has impacted more than 1 million families through its education and outreach programs. Click here to download our free news, weather and smart TV apps. And click here to stream Channel 9 Eyewitness News live.
Yahoo
an hour ago
- Yahoo
Popular Aldi snack recalled due to potential ‘life-threatening' allergen
Aldi is recalling one of its sweet treats due to the presence of an undeclared allergen. The U.S. Food and Drug Administration (FDA) issued a notice on Tuesday to announce that Camerican International was recalling 7.05 oz boxes of Casa Mamita Churro Bites Filled with Chocolate Hazelnut Cream. The recall was issued because the Aldi brand snack may contain undeclared milk, so consumers with an allergy or 'severe sensitivity to milk run the risk of serious or life-threatening allergic reaction,' per the FDA. The recalled churro bites were distributed at Aldi stores in 13 states: Alabama, Arkansas, Florida, Georgia, Iowa, Illinois, Kentucky, Louisiana, Missouri, Mississippi, North Carolina, South Carolina, and Tennessee. The 7.05 oz cardboard boxes are marked with a 'Best If Used By' date of July 14, 2025, and the Lot Number '01425.' According to the FDA, the recall was initiated after a 'consumer discovered that the milk-containing product was distributed in packaging that did not reveal the presence of milk.' A subsequent investigation revealed the mistake was a result of a 'temporary breakdown in the company's production and packaging processes,' which has since been corrected. However, there have been no illnesses reported to date due to this product. Consumers are now urged to return the churro bites to the place of purchase for a full refund. This isn't the first time Aldi food item to be recalled recently. In May, Santa Monica Seafood of Rancho Dominguez, California, issued a voluntary recall on its Atlantic Salmon Portions with Seafood Stuffing because they may have contained undeclared soy. The affected salmon portions were sold in three states: California, Nevada, and Arizona. The products were sold in 16-ounce packages and had a use/freeze-by date of June 2, 2025. The last two years have also seen an alarming and unexplained rise in recalls. In 2024, approximately 300 food recalls were issued, with those recalls being linked to nearly 1,400 illnesses, a Public Interest Research Group report revealed. Out of the 1,400 illnesses, 487 people became sick enough to require hospitalization, and 19 people died. While those numbers are still low when weighed against the entire U.S. population, they are also double the number of hospitalizations and deaths from food-borne illnesses in 2023. Earlier in May, cucumbers sold across the country were recalled after people in 15 states reported getting ill from salmonella. Florida-based Bedner Growers, Inc. recalled the vegetables distributed by Fresh Start Produce Sales, Inc. from April 29 to May 19.
